ICER’s Final Evidence Report on Biogen’s Aduhelm Released, Notes Insufficient Clinical Evidence for Overly Expensive Alzheimer’s Drug

The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report on aducanumab, Biogen’s infamous Alzheimer’s drug. The report highlights the lack of concrete clinical evidence regarding the drug’s clinical benefits and its high price tag. ICER recommends a yearly cost of $3,000 to $8,400 per year, rather than the current $56,000 list price.

ICER’s Chief Medical Officer Dr. David Rind remarks, ““The clinical trial history and evidence regarding aducanumab are complex,” adding, “We have spent eight months analyzing the study results, talking with patient groups and clinical experts, and working with the manufacturer to understand their position.  At the conclusion of this effort, despite the tremendous unmet need for new treatments for Alzheimer’s disease, we have judged the current evidence to be insufficient to demonstrate that aducanumab slows cognitive decline, while it is clear that it can harm some patients.” Read more here.

(Source: ICER, 8/5/21)